ZZ Biotech Announces FDA Fast Track Designation for Stroke Program

HOUSTON, USA, June 12, 2020 / B3C newswire / — ZZ Biotech today announced that the US Food and Drug Administration (FDA) has designated the investigation of the company’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program.

Read full press release here.